Active — Not RecruitingPhase 2

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

United States59 participantsStarted 2014-10

Plain-language summary

The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Planned to undergo allo-HSCT * Age ≥ 18 years Exclusion Criteria: * As determined by the study investigators or consenting professionals, prolonged antibiotic treatment, as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing antianaerobic antibiotics * Has severe colitis of any etiology or a history of inflammatory bowel disease (IBD).

What they're measuring

Clostridium difficile infection (CDI)

Timeframe: up to 1 year following randomization

Trial details

NCT IDNCT02269150

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10

View on ClinicalTrials.gov More Allogeneic Hematopoietic Stem Cell trials